This composite educational image illustrates multi-organ manifestations of amiodarone toxicity through diagnostic imaging and clinical photography. Panel A shows FDG PET-CT scans: the whole-body coronal view (A-1) displays multiple hypermetabolic lesions throughout the lung fields, while the axial thyroid view (A-2) shows no abnormal tracer uptake. Panel B presents a technetium-99m pertechnetate thyroid scintigraphy scan, demonstrating diffuse, homogenous tracer uptake in both lobes, characteristic of type 1 amiodarone-induced thyrotoxicosis in the context of Graves' disease. Panel C is a slit-lamp biomicroscopy photograph of the cornea, highlighting 'vortex keratopathy' (cornea verticillata). A yellow circle denotes the characteristic dense, gray granular lines forming a swirling, vortex-like pattern radiating from the inferior corneal region. Together, these images demonstrate the systemic impact of amiodarone, including pulmonary toxicity (hypermetabolic lung lesions), thyroid dysfunction, and ocular side effects (corneal deposits).

This composite educational figure illustrates the anti-angiogenic effects of Amiodarone using a mouse Matrigel plug assay. Panel A and B present clinical photographs of Matrigel plugs in situ and post-excision. The control group shows deep red, bloody plugs with extensive surrounding vasculature, while the Amiodarone-treated group exhibits pale, translucent plugs with significantly reduced vessel formation. Panel C shows light microscopy images of histological sections (400x magnification) stained with anti-CD31 antibodies (DAB-brown) and Gill’s Hematoxylin (blue nuclei). The control section demonstrates numerous brown-stained vascular structures with open lumens (indicated by arrows), whereas the treated section shows sparse CD31 positivity and a lack of organized vessel architecture. Panel D contains flow cytometry (FACS) dot plots comparing CD31+ / CD45- endothelial cell populations (highlighted in red squares). The plots demonstrate a quantitative reduction in infiltrating endothelial cells in the Amiodarone-treated plugs compared to the untreated control. This image is relevant for studying pharmacological inhibition of angiogenesis and tumor microenvironment modulation.

Educational medical graphic depicting corneal biomechanical analysis through Optical Coherence Tomography (OCT) and strain measurement. Panel (a) presents a cross-sectional structural OCT image of a cornea, divided into a cross-linked region (CXL) and an untreated region (UT). Visually, the CXL side demonstrates a notable reduction in corneal thickness and altered optical scattering compared to the thicker, untreated UT side. Panel (b) features a line graph correlating intraocular pressure (IOP) with cumulative tissue strain over an 8-second interval. The graph shows that under a pulsed IOP load (black line, 11.75 to 12.25 mmHg), the CXL cornea (red curve) exhibits significantly lower cumulative strain (mε) than the UT cornea (blue curve). This visual comparison highlights the increased mechanical stiffness and structural changes resulting from corneal cross-linking treatment, a common ophthalmic procedure for keratoconus. The image serves as a clinical demonstration of how optical coherence elastography (OCE) can monitor and quantify the effects of corneal strengthening interventions.

This educational digital illustration depicts the RANKL-RANK-OPG regulatory axis governing osteoclast development and bone resorption. The left panel shows osteoblasts secreting RANKL (receptor activator of NF-kB ligand) that engages RANK on osteoclast precursors, promoting osteoclast maturation and bone-resorbing activity; osteoclasts become mature osteoclasts at the bone surface, initiating resorption on a cortical or trabecular bone interface. The right panel demonstrates pharmacologic inhibition by denosumab, a human monoclonal antibody that binds RANKL and prevents RANK-RANKL signaling, thereby blocking osteoclast formation, reducing resorptive function, and decreasing osteoclast survival. In this inhibited scenario, osteoblasts continue signaling but osteoclastogenesis is suppressed, leading to reduced cavitation and diminished bone turnover. The image also references osteoprotegerin (OPG) as the endogenous decoy receptor for RANKL. The layout includes legend items labeling RANKL, RANK, denosumab, and OPG, and captions Osteoclast Stimulation and Osteoclast Inhibition. Although schematic, the depiction captures clinically relevant concepts: denosumab therapy for osteoporosis and Paget disease when bisphosphonates are contraindicated (e.g., renal failure). This illustration supports educational understanding of antiresorptive therapy, mechanism of action, and pathway interactions, useful for teaching, review, and clinical discussion about bone remodeling, osteoclast biology, and targeted osteoporosis treatment. This educational figure is intended for medical students, residents, and clinicians.

Summary : This figure illustrates the cellular mechanisms of bone formation and resorption, and the effects of two classes of drugs (denosumab and bisphosphonates) on osteoclast development and activity. It is divided into three panels (A, B, C) showing normal physiology, denosumab action, and bisphosphonate action, respectively. process diagram: # Panel A: Normal Bone Remodeling : • Precursor cells (CFU-GM) differentiate into pre-osteoclasts under the influence of hormones, growth factors, and cytokines. • Osteoblasts produce RANKL, which binds to RANK on pre-osteoclasts, promoting their maturation into multinucleated osteoclasts. • Activated osteoclasts resorb bone, while osteoblasts form bone, maintaining bone homeostasis. # Panel B: Denosumab Action : • Denosumab (depicted as Y-shaped antibodies) binds to RANKL, preventing its interaction with RANK on pre-osteoclasts. • This inhibits the formation, function, and survival of osteoclasts (multinucleated osteoclast faded out). • Bone resorption is inhibited, while bone formation by osteoblasts continues. # Panel C: Bisphosphonate Action : • Precursor cells and RANKL-RANK signaling proceed as in normal physiology, allowing osteoclast formation. • Bisphosphonate (depicted as pink triangles) acts on activated osteoclasts, inactivating them and inducing apoptosis. • Inactivated osteoclasts cannot resorb bone, and apoptotic osteoclasts are removed. • Bone resorption is inhibited, while bone formation by osteoblasts continues. # Nodes : • Precursor cells (CFU-GM) (circle) • Pre-osteoclast (circle) • Multinucleated osteoclast (large circle with nuclei) • Activated osteoclast (large cell with ruffled border) • Inactivated osteoclast (large cell, faded) • Apoptosis (fragmented cell) • Osteoblasts (row of blue cells) • Hormones, growth factors, cytokines (colored dots) • RANK/RANKL (small squares) • Denosumab (Y-shaped antibodies) • Bisphosphonate (pink triangles) # Connectors : • Arrows show differentiation from precursor to pre-osteoclast to multinucleated osteoclast. • RANKL arrows from osteoblasts to pre-osteoclasts. • In panel B, red inhibitory line from pre-osteoclast to multinucleated osteoclast. • In panel C, arrow from bisphosphonate to activated osteoclast, then to inactivated osteoclast and apoptosis. # Layout : • Each panel is arranged horizontally: precursor cells on the left, osteoblasts at the bone surface, osteoclast lineage above the bone, and bone formation/resorption processes below. • Drug actions are superimposed on the normal pathway in panels B and C. # Analysis : • The figure demonstrates that normal bone remodeling involves a balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. • Denosumab inhibits osteoclast formation by blocking RANKL, preventing bone resorption. • Bisphosphonates inactivate and induce apoptosis in mature osteoclasts, also inhibiting bone resorption. • Both drugs preserve bone formation while reducing bone loss, but act at different stages of the osteoclast lifecycle.

A medical signaling pathway diagram illustrating two mechanisms (a and b) by which active vitamin D compounds inhibit bone resorption by modulating RANKL expression. Mechanism (a) shows active vitamin D inducing an 'alteration in the calcium endocrine system,' which leads to the suppression of RANKL expression on the surface of osteoblastic cells, evidenced by a reduction in surface-bound RANKL molecules (red circles). Mechanism (b) depicts 'changes in the cellularity of osteoblastic cells,' where active vitamin D influences the differentiation of mesenchymal progenitors. This results in a population shift toward osteoblastic cells with lower RANKL expression. The right panel outlines the osteoclastogenic lineage, showing the progression from hematopoietic cells to cell-cycle-arrested quiescent osteoclast precursors (QOPs), and finally to multinucleated osteoclasts. A red inhibitory bar indicates that active vitamin D potentially blocks the maturation of QOPs into active osteoclasts, while having 'no effect' on the initial hematopoietic-to-QOP transition.

Educational medical composite image illustrating diagnostic findings of osteoporosis and an associated vertebral compression fracture. Panel A displays a Dual-Energy X-ray Absorptiometry (DEXA) report including a coronal lumbar spine scan (L1-L4), a densitometry table showing a critical T-score of -4.8 at L4, and a corresponding bone mineral density (BMD) graph. The graph plots BMD (g/cm²) against age, with color-coded reference ranges: green for normal, yellow for osteopenia, and red for osteoporosis; the patient's data point falls significantly within the osteoporosis range. Panel B presents a sagittal view MRI of the lumbar spine using a Short Tau Inversion Recovery (STIR) sequence. The MRI reveals a wedge-shaped deformity and hyperintense signal at the L1 vertebral body, characteristic of bone marrow edema from an acute osteoporotic compression fracture. Normal rectangular morphology is maintained in T12 and L2-L4. This visual set demonstrates the correlation between quantitative bone density measurements and clinical pathology in geriatric orthopedics.

Light microscopy examination of a decalcified vertebral cancellous bone section from the vertebral body, stained with Hematoxylin and Eosin. The specimen demonstrates osteoporotic microarchitecture with thinning and dropout of bone spicules. The trabecular network shows enlarged intertrabecular spaces and extensive perforations, yielding a porous, lattice-like appearance. Horizontal trabeculae are thinner and there is loss of interconnectivity between trabecular plates, consistent with reduced bone strength. The endplates and cortical shell are variably preserved in this plane, while the marrow spaces appear expanded. These histologic features reflect diminished bone mass and compromised structural integrity. Clinically, this pattern is typical of osteoporosis or severe osteopenia, often associated with aging or postmenopausal status, and correlates with increased vertebral fracture risk. Differential considerations include disuse osteoporosis and other metabolic bone diseases when osteoid deposition or mineralization abnormalities are prominent. The diagnostic relevance lies in correlating histology with radiographic bone density (DEXA) and clinical risk factors, guiding therapy decisions such as antiresorptive or anabolic agents. This image serves educational purposes in teaching vertebral trabecular bone histology, osteoporosis pathology, and microarchitectural deterioration. Potential research applications include evaluating therapeutics aimed at preserving trabecular connectivity and vertebral strength. This histology correlates with radiographic densitometry and fracture risk in patients.

Dual-energy X-ray absorptiometry (DEXA) scan report presenting bone mineral density (BMD) analysis of the lumbar spine and proximal femur. The image is divided into two clinical diagnostic panels. The left panel shows the lumbar spine (L1–L4) with segmented vertebral regions, an associated fracture risk graph plotting BMD against age, and a quantitative 'Results Summary' table. The highlighted total T-score of -5.1 for the lumbar spine is significantly below the -2.5 threshold, indicating severe osteoporosis. The right panel displays the proximal femur (hip) with demarcated regions for the femoral neck, trochanter, and intertrochanteric area. Its corresponding fracture risk graph shows a data point deep within the red 'High Risk' zone. The summary table for the femur highlights a total T-score of -3.8, confirming a diagnosis of osteoporosis. Both panels include Z-scores, peak reference percentages (PR), and age-matched percentages (AM). This comparison chart illustrates diagnostic imaging and metabolic bone disease assessment for clinical education on osteoporosis classification and fracture risk stratification.